JG
ADMA icon

Joel Greenblatt’s ADMA Biologics ADMA Stock Holding History

Joel Greenblatt’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618K Buy
+73,829
New +$673K ﹤0.01% 1463
2026
Q1 		– Sell
-13,627
Closed -$249K – 1753
2025
Q4 		$249K Buy
13,627
+2,616
+24% +$44.1K ﹤0.01% 1616
2025
Q3 		$161K Sell
11,011
-97,982
-90% -$1.68M ﹤0.01% 1632
2025
Q2 		$1.98M Sell
108,993
-55,254
-34% -$1.13M 0.01% 932
2025
Q1 		$3.26M Sell
164,247
-2,447
-1% -$42.3K 0.03% 647
2024
Q4 		$2.86M Buy
166,694
+2,129
+1% +$40.1K 0.03% 639
2024
Q3 		$3.29M Buy
164,565
+86,417
+111% +$1.34M 0.03% 597
2024
Q2 		$874K Sell
78,148
-17,332
-18% -$145K 0.01% 927
2024
Q1 		$630K Buy
95,480
+25,891
+37% +$142K 0.01% 973
2023
Q4 		$315K Sell
69,589
-6,030
-8% -$22.3K 0.01% 1126
2023
Q3 		$271K Buy
75,619
+14,564
+24% +$56.1K 0.01% 1141
2023
Q2 		$225K Buy
61,055
+29,532
+94% +$109K ﹤0.01% 1201
2023
Q1 		$104K Sell
31,523
-10,987
-26% -$38K ﹤0.01% 1287
2022
Q4 		$165K Buy
+42,510
New +$131K ﹤0.01% 1146

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Joel Greenblatt's ADMA Position: Q2 2026 in Review

Joel Greenblatt opened a new position in ADMA Biologics (ADMA) in Q2 2026: 73,829 shares worth $618K. The stake represents ﹤0.01% of the portfolio and ranks #1463 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in ADMA as recently as Q4 2025.

Joel Greenblatt first reported a position in ADMA in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.29M in Q3 2024. 321 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Joel Greenblatt held 73,829 shares of ADMA Biologics worth $618K as of Q2 2026.
  • ADMA Biologics was a new Joel Greenblatt position in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1463 holding.
  • Joel Greenblatt first reported a position in ADMA Biologics in Q4 2022 and has held it in 14 quarters since.
  • Joel Greenblatt's ADMA Biologics position peaked at $3.29M in Q3 2024.
  • 321 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.